Literature DB >> 10098796

The prevalence of hepatitis B infection in adults in England and Wales.

N J Gay1, L M Hesketh, K P Osborne, C P Farrington, P Morgan-Capner, E Miller.   

Abstract

Cost effectiveness analyses of alternative hepatitis B vaccination programmes in England and Wales require a robust estimate of the lifetime risk of carriage. To this end, we report the prevalence of infection in 3781 anonymized individuals aged 15-44 years whose sera were submitted in 1996 to 16 microbiology laboratories in England and Wales. One hundred and forty-six individuals (3.9%) were confirmed as anti HBc positive, including 14 chronic carriers (0.37%). The prevalence of infection and carriage was higher in samples collected in London and increased with age. No increased risk of infection was seen in sera from genito-urinary (GUM) clinics. Only 15 sera positive for hepatitis B were also positive for hepatitis C. Our results confirm the low prevalence of hepatitis B in England and Wales, are consistent with previous estimates of carriage and suggest that many infections were acquired while resident outside the UK. Future prevalence studies should determine the country of birth and other risk factors for each individual in order to confirm these findings.

Entities:  

Mesh:

Year:  1999        PMID: 10098796      PMCID: PMC2809598          DOI: 10.1017/s0950268898001745

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  10 in total

Review 1.  Treatment of chronic hepatitis.

Authors:  P J Gow; D Mutimer
Journal:  BMJ       Date:  2001-11-17

2.  Hepatitis B virus transmission in The Netherlands: a population-based, hierarchical case-control study in a very low-incidence country.

Authors:  S J M Hahné; I K Veldhuijzen; L J M Smits; N Nagelkerke; M J W van de Laar
Journal:  Epidemiol Infect       Date:  2007-04-04       Impact factor: 2.451

3.  Impact of universal preadolescent vaccination against hepatitis B on antenatal seroprevalence of hepatitis B markers in British Columbia women.

Authors:  Meenakshi Dawar; David M Patrick; Mark Bigham; Darrel Cook; Mel Krajden; Helen Ng
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

4.  Epidemiology and transmission of hepatitis B and C viruses in Kazakhstan.

Authors:  Zhannat Z Nurgalieva; F Blaine Hollinger; David Y Graham; S Zhangabylova; Abai Zhangabylov
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

5.  The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis.

Authors:  Richard Conway; Michele F Doran; Finbar D O'Shea; Brendan Crowley; Gaye Cunnane
Journal:  Clin Rheumatol       Date:  2014-04-13       Impact factor: 2.980

6.  Hepatitis B immunity in Australia: a comparison of national and prisoner population serosurveys.

Authors:  H F Gidding; D Mahajan; J Reekie; A R Lloyd; D E Dwyer; T Butler
Journal:  Epidemiol Infect       Date:  2015-01-20       Impact factor: 4.434

7.  11. Cancers attributable to infection in the UK in 2010.

Authors:  D M Parkin
Journal:  Br J Cancer       Date:  2011-12-06       Impact factor: 7.640

8.  Prevalence of chronic hepatitis B and hepatitis C among first time blood donors in Northeast Bosnia and Herzegovina: an estimate of prevalence in general population.

Authors:  Jasminka Petrovic; Nermin N Salkic; Sead Ahmetagic; Vildana Stojic; Slavica Mott-Divkovic
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660

9.  Use of laboratory-based surveillance data to estimate the number of people chronically infected with hepatitis B living in Scotland.

Authors:  C Schnier; L Wallace; K Tempelton; C Aitken; R N Gunson; P Molyneaux; P McINTYRE; C Povey; D Goldberg; S Hutchinson
Journal:  Epidemiol Infect       Date:  2013-12-17       Impact factor: 4.434

10.  Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016.

Authors:  Nick Bundle; Sooria Balasegaram; Sarah Parry; Sadna Ullah; Ross J Harris; Karim Ahmad; Graham R Foster; Cheuk Yw Tong; Chloe Orkin
Journal:  Euro Surveill       Date:  2019-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.